3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
60
Neoplasm Metastasis
6
Neoplasms
4
Endometrial Neoplasms
4
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Ovarian Neoplasms
2
Neuroblastoma
2
Neoplasms by Site
2
Melanoma
2
Hereditary Sensory and Autonomic Neuropathies
2
Glioma
2
Glioblastoma
2
Carcinoma, Ovarian Epithelial
2
Breast Diseases
2
Anatomic Stage II Breast Cancer AJCC v8
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Sarcoma
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Meningioma
1
Medulloblastoma
1
Interventions
ribociclib
1
Drug Therapy, Combination
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
HR+HER2- Advanced Breast Cancer
×
ribociclib
×
1 year
×
Clear all
NCT06148506
2025-12-05
ValerEE
Novartis
Active not recruiting
376 enrolled